বঙ্গবন্ধু শেখ মুজিব মো Bangabandhu Sheikh Mu শাহবাগ, ঢাক	IRB	APPLI	CATION FORM	
RESEARCH PROTOCOL	FOR OFFICE USE ONLY			
Number: Version No.	IRB Meeting:	□ Yes	□ No	Date: 23-Dec-2024
Version date:	IRB Approval:	☐ Yes	□No	Date:
		□ Yes	□ No	Date:
		☐ Yes	□No	Date:

Institutional Review Board (I.R.B) Application Form

01.	Title of the study	:				
02.	Name of the Researcher/ Principal Investigator	:				
05.	Name of Institute	:				
08.	Co-Investigators	:				
09.	Place of Study	:				
10.	Type of study	: (Check all tha	nt Apply)			
	☐ Case Control study		☐ Programme (Umbrella Project)			
	☐ Clinical Trial (Hospital/Clinic/F	ield) *	☐ Prophylactic Trial			
	☐ Community-based Trial/Interven	ntion	☐ Record Review			
	☐ Cross Sectional		☐ Secondary Data Analysis			
	☐ Longitudinal Study		☐ Surveillance/Monitoring			
	☐ Meta-analysis		☐ Systemic Review			
	☐ Health Programme Evaluation/ (improvement	Quality	☐ Curriculum Evaluation Study			
	☐ Randomized Controlled trial		☐ Pilot/Feasibility Study			
	☐ Cohort Study (Prospective and r	etrospective)	☐ Registry-Based Studies			
	☐ Surveillance /Monitoring		☐ Outbreak Investigation			
	☐ Risk factor analysis		☐ Retrospective Chart Reviews			
	☐ Use of existing Databases		☐ Medical wearables and Sensors Study			
	☐ Investigational Device Exemption	on (IDE) Study	☐ Mixed methods research combining			
			qualitative and quantitative			
	☐ Other (Specify):		and quantitative			
11.	Duration of study	•				
	7	•				
12.	Study Population: Sex, Age, Spec	cial Group and				
	Research Subject:		Special Group:			
	☐ Human		☐ Pregnant Women			
	☐ Animal		☐ Fetuses			

	☐ Microorganism	☐ Prisoners					
	☐ Other (specify):	□ Destitute					
		☐ Service Provides					
	Sex	☐ Cognitively Impaired					
	☐ Male	☐ Expatriates					
	Female	☐ Immigrants					
	☐ Transgender	□ Refugee					
	A	☐ Other (specify):					
	Age:	Ethnicity:					
	$\Box 0 - 4 \text{ Years}$	□ No ethnic selection (Bangladeshi)					
	□ 5 – 10 Years	☐ Other (specify):					
	☐ 11 – 17 Years						
	☐ 18 – 64 Years						
13.	Gargant Process (Chash all that arrely)	Tananaga					
13.	Consent Process: (Check all that apply) ☐ Written	Language: □ Bangla					
	☐ Oral ☐ Audio	☐ English					
		☐ Other (specify):					
	□ Video						
	□ None						
	a) Will study tools/questionnaire be used for this	☐ Yes ☐ No ☐ NA					
	protocol?	(If yes, tools/ questionnaire must be attached)					
	b) Will there be any legally authorized	\square Yes \square No \square NA					
	representative (LAR)?						
	c) Will there be an impartial witness (If the	\square Yes \square No \square NA					
	participant is illiterate)?						
	d) In order to participate in research with children, is	\square Yes \square No \square NA					
	assent being taken?						
	e) For research involving pregnant woman,	☐ Yes ☐ No ☐ NA					
	consideration of risks with potential benefit for the						
	fetus and pregnant women has been properly addressed?						
16.	Proposed Sample Size:	1					
	Sub-group (Name of subgroup e.g. Men, Women)	and Number					
17	Study Site:						
L							
18.	Collaborating Institute (s): Please provide full of	ficial address					
	Institution/ Department # 1						
	Name						
	Contact person						
	Department						
	Institution						
	Directorate						
	(in case of GoB i.e. DGHS)						
	Ministry						
	Other:						

	Collaborating Institute (s): Please provide full official address									
	Institution/ Department # 2									
	Name									
	Contact person									
	Department									
	Institution									
	Directorate									
	(in case of GoB i.e. DGHS)									
	Ministry									
19.	Determination of Risk: Does the	Research Invol	lve (Check a	ll that apply)						
1).	` 112/									
	☐ Human exposure to radioactive	agents?		-	fectious agents	5?				
	☐ Fetal tissue or abortus?			ational new di	· ·	1 . /				
	☐ Investigational new device? Specify:		sources?	data avanabi	e via public arc	enives/				
	specify.			rical or diagno	ostic clinical sp	ecimen				
	☐ Existing data available from De	nartment?	only?	gical of diagno	ostic cilinear sp	CCIIIICII				
	Laisting data available from Dej	partificit:	☐ Observation of public behavior?							
				atment regime						
19.	Will the data be recorded in a w	ay that allows								
	identified either directly or through				□ Yes	□ No				
	Does the research address sensitive									
	sexual behavior, alcohol consump	otion, or illegal	activities s	uch as drug	☐ Yes	□ No				
20.	use? Does the study involve any biohaza	organisms		1						
20.	of risk group 2, 3, or 4?	☐ Yes	□ No							
	Biological Specimen use	□ Yes	□No							
	Will the biological specimen be sto	□ Yes	□No							
	If the response is 'yes', how long the									
	preserved?					_				
	Will the specimens be shipped to o	•			□ Yes	□No				
	If yes, name of institution(s) and co	•				- 110				
	Who will be the custodian of the sp			1 -						
	Who will be the custodian of the sp Bangladesh?	becimen when s	nippea outsi	ie						
	Who will be the owner(s) of the spe	ecimens?								
	Will the consent be obtained from		pants for use	e of the						
	preserved specimen for other initia				□ Yes	□ No				
	their re-consent?									
	Has a MoU been signed with regar	and	□ Yes	□No						
2.1	ownership of specimen?		L 103							
21.	Do you consider this research? (0	eck one)								
		☐ No more th		Γ						
	☐ Greater than minimal risk	☐ Only part	of the diagnos	tic test						
	E 1:	Г 1:								
	Explain	Explain		Explain						

22. (Contribu	tion by th	e Memb	ers of th	e Team:								
Meml	bers'					Contribution							
Name	•	Research Idea/ concept	Study Design	Protocol writing	Respond to Reviewers and document	at IRB	Developing Data collection Tool(s)	Data collection	Data analysis and interpretation	Manuscript writing			
						,							
23.	Disse	emination	type	Res _j No	onse Yes	D	escription	(if the res	sponse is a y	es)			
	shared v of publ presenta	vith stakeho ication, suc tions at inte	olders, sp ch as w	ecifying to orking particular par	hem if kno apers, into aces, semin	own, and the	methods to tional) pub	be used. In lications,	e research find dicate the anti international	cipated type			
	Seminar												
	Internal publication												
		Vorking paper											
	DGHS/	ring with GoB (e.g. HS/ Ministry, others)											
	Sharing NGOs	g with natio	onal										
	Present internat worksh		nce										
	Peer-re												
	Sharing internat	with agen	cies										
	Policy l	orief											
23.	Fundin	ıg:				Yes		□No)				
	Is the p	rotocol ful	ly funde	d?				·					
	If the ar	nswer is ye	-		,								
	sponsor's name Is the protocol partially funded? If the answer is yes, please provide				F								
						□ Yes)				
	sponsor's name).							
	If fund	has not b	een ider	ntified:	•								
	Is the proposal being submitted for funding?					☐ Yes		□N	O				
		name of the	fundin	g agency				<u> </u>					
				- •									

Ī	24.	Conflict of interest:								
		Do any of the participating investigators and/or member(s) of their immediate families have an								
		equity relationship (e.g. stockholder) with the sponsor of the project or manufacturer and/or owner								
		of the test product or device to be studied or serve as a consultant to any of the above?								
		☐ No ☐ Yes ((please submit a written statement of disclosure to the BSMMU)								

I hereby certify that the information provided is true, complete, and accurate to the best of my knowledge. I understand that any false, fictitious, or fraudulent statements or claims may result in criminal, civil, or administrative penalties. I accept responsibility for the scientific integrity of the project and commit to submitting the necessary progress reports, including updating protocol details, if this application results in a grant award.

We agree to obtain approval of the Institutional Review Board of BSMMU for any changes involving the rights and welfare of subjects or any changes of the Methodology before making any such changes.

Principle Investigator

Comments of Reviewer 1	Comments of Reviewer 2
☐ Can be accepted	☐ Can be accepted
☐ Can be accepted with minor corrections	☐ Can be accepted with minor corrections
☐ Can be accepted with major corrections	☐ Can be accepted with major corrections
☐ Reject and rewrite the Protocol	☐ Reject and rewrite the Protocol
Name and signature	Name and signature
Date:	Date:
Seal	Seal

Put Tick sign ($\sqrt{}$) against appropriate answers to each of the following statement (If not Applicable, Please write N/A)

	Proto	ocol Number:							Version No.; Version	date:			
	Princ	Principal											
	Investigator												
Ī	Protocol Title:												
01.	Stud	ly population:		Yes	No		(e)	Benefits to be derived]			
	(a)	Ill participants						(f)	Right to refuse to participate	or to	1		
	(b)	Non-ill participants							withdraw				
	(2)	Minor or persons under guardianship				 	-	(~)	from the study Confidential handling of data		-+		
	(c)						-	(g))				
	(d)	Others: Pregnar				(h)	Provision for compensation		[
02.	Dog	a the atudy invol			Yes	No	05.	Dro	cautions to be taken to protect		<u></u>	No	NA
02.	Does the study involve: (a) Physical risk to participants						05.	Precautions to be taken to protect anonymity of study participants					
	(b)	Social risk to pa						uno					Ш_
	(c)	Psychological r		ants			06.	The	following have been included	l Ye	26	No	NA
	(d)	Discomfort to p		11113			00.	(a)	IRB Project Summary				
		Invasion of part		***			-		Consent form for adult partic	inon 🗆			
	(e)						-	(b		-			
	(f)	Disclosure of into participants of		agıng				(c)	Consent form from parent or guardian	. 🗆			
	[to participants (JI OHIEIS				-	(d)	Assent form		-		
03.	Doe	Does the study involve use of				No		(e)	Consent form of previous stu				
05.	(a)	Body fluids or organs						(f)	MOU				
	(c)	·					-	(h)	Questionnaire/Research instr				
	, ,	other)				(11)	Questionnane/Research histi	rume 🗌					
	(d)	Stored biologic	_										
	(e) Data from Previous study												
04.		rmed written con	isent/assent be	Y	No	NA							
		ined from: Adult participar		es	┼	+	-						
	(b)	Parent or guard		\Box			-						
	(0)	kin (if participa											
		years of age/or											
		guardianship)											
	(c)	Participants age (Assent)	d 11-17 years										
	<u> </u>	(Assent)											
	Lagr	ee to ahide hy t	he approved r	rotocc	al and o	chall o	htain	nric	or approval of the IRB for an	ny chanc	es in	,	
	_	orotocol.	ne approved p	101000	n and s	311a11 O	otam	pric	approvar of the IKB for an	ry Chang	,cs III		
	the p	1010001.											
	Princ	cipal Investigate	or										
	na 6			ID	D doc/1	2/2101	וארוב	/NI\ /1					

INSTRUCTIONS FOR PREPARATION OF AN PROTOCOL FOR THE INSTITUTIONAL REVIEW BOARD (IRB), BSMMU

<u>Check documents being submitted here with to Board (Total eight copies should be submitted):</u>

- IRB Application form
- List of abbreviation
- Abstract
 - 1. Principal investigator
 - 2. Research Protocol title
 - 3. Proposed start date
 - 4. Estimated end date
 - 5. Background information (in brief)- Burden, Knowledge gap, relevance and rationale
 - 6. Hypothesis to be tested/ Research Question
 - 7. Objectives
 - 8. Study design and methodology
 - 9. Outcome variables/ Outcome measurement

• Description of the Research project

1. Background of the project [Establish the scientific validity of the hypothesis by grounding it in the background information of the proposed study and referencing prior research on the topic. Address the relevance of sex, gender, and diversity factors, such as ethnicity and socioeconomic status (SES), and support the discussion with specific references. Critically evaluate the existing body of knowledge, highlighting the questions and gaps that remain unresolved and need to be addressed to meet the proposed objectives. If the subject lacks adequate information, emphasize the necessity of generating new insights to advance understanding in the field.]

2. Study design and methodology

[This research will employ a well-defined design and methodology to achieve its specific aims. The study will adhere to strict laboratory protocols, including the use of personal protective equipment (PPE), aerosol confinement techniques, and, if necessary, BSL2 or BSL3 laboratory facilities for specific procedures. The study population will be clearly defined with inclusion and exclusion criteria, supported by a robust sampling strategy to ensure relevance and representativeness. Primary outcome and exposure variables will be identified and measured using validated data collection tools, with follow-up plans incorporated if applicable. The methodological approach, whether biomedical, social, gender-sensitive, or environmental, will be scientifically justified to ensure validity. Potential limitations and challenges will be acknowledged, with strategies outlined to mitigate them, ensuring the robustness of the research process.]

- a) Study duration
- b) Study site/s
- c) Study population
- d) Selection Criteria
- e) Sample size calculation [State the assumptions clearly, including those related to the study population and data reliability. Specify the desired power (e.g., 80%) and precision level (e.g., 0.05 significance level). Describe the optimal conditions necessary to achieve the required sample size, such as accessibility to a large population, low dropout rates, and efficient sampling strategies.]
- f) Patient enrollment and data collection
- g) Study procedure
- h) Sample collection procedure
- i) Method details (lab procedure/ other methods applied- in details)
- j) Follow up of the enrolled patients (if any planned)
- k) Operational definition

- 1) Data safety monitoring Plan (DSMP) if required
- m) Study flow chart
- 3. Data Analysis [Outline the data analysis plans, including a detailed strategy for stratifying results by sex, gender, and diversity factors such as ethnicity and socioeconomic status. Specify whether the investigators will perform the analysis or if it will be outsourced to other professionals. Clearly state the statistical software packages to be used (e.g., SPSS, R, or STATA). If the study is blinded, explain when the blinding code will be opened. For clinical trials, mention whether interim data analysis will be conducted to guide decisions on the study's future course. Ensure all procedures align with the study objectives and ethical standards.]
- 4. Data storage and record keeping
- **5. Ethical Assurance for Protection of Human rights** [Describe the procedures to ensure privacy of the participants]
- **6. Patient** / **participant confidentiality** [Include a description of the methods for safeguarding confidentiality of data and protecting anonymity of the participant.]
- **7. Use of animal** (if applicable) [Describe if and the type and species of animals to be used in the study. Justify with reasons the use of particular animal species in the research and the compliance of the animal ethical guidelines for conducting the proposed procedures.]
- **8. Potential risk of the project** [Describe any potential physical, psychological, social, legal or other risks and seriousness of such risks. If methods of research create potential risks, describe other methods, if any, that were not considered for specific reasons. Describe procedures for protecting against or minimizing potential risks and an assessment of their likely effectiveness.]
- **9. Collaborative arrangement** [Describe if this study involves any scientific, administrative, fiscal, or programmatic arrangements with other national or international organizations or individuals. Indicate the nature and extent of collaboration and include a letter of agreement between the applicant or his/her organization and the collaborating organization.]
- 10. Literature cited [Identify all cited references to published literature in the text by number in parentheses. List all cited references sequentially as they appear in the text. For unpublished references, provide complete information in the text and do not include them in the list of Literature Cited. There is no page limit for this section, however, exercise judgment in assessing the "standard" length]
- **11. Detailed budget and budget justification**. [Please provide one-page statement justifying the budgeted amount for each major item, including the use of human resources, major equipment, and laboratory services]

Appendix 1: Information sheet for participation (English and Bangla)

Appendix 2: Consent for participants/ assents

Appendix 3: Questionnaire (English)/ Case record form

Appendix 4: Questionnaire (Bangla)

Appendix 5: SOP/Laboratory manuals